|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Fresenius Medical Care AG & Co. KGaA, a global provider of dialysis products and services. |
|---|---|
| Transferring Party | Renal Solutions, Inc., a providor of sorbent dialysis therapy. |
| Sector | Medical Devices |
| Date | November 29, 2007 |
| Analysis As the innovator in the sorbent technology field, RSI holds key patents and other IP for purifying tap water to dialysate quality and allowing dialysate to be regenerated. This reduces the water volume requirement for a typical hemodialysis treatment, a step toward the development of a "wearable kidney". Fresenius sees the current market size of the home peritoneal dialysis and hemodialysis markets at about $2b, with the potential to double in the next 10 years. Deal value -- 160m plus $30m in possible milestone payments. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |